NORD gratefully acknowledges Raphael Pollock, MD, PhD, Professor of Surgery, Director of Surgical Oncology, Chief of Surgical Services, The Ohio State University-The James, for assistance in the preparation of this report.
SummaryDesmoid tumor commonly develops in the fibrous (connective) tissue of the body that forms tendons and ligaments, usually in the arms, legs or midsection, and also in the head and neck. These tissues of the body connect, support, and surround other body parts and organs. The myofibroblast is the cell considered to be responsible for the development of desmoid tumor. Regardless of its scientific classification, a desmoid tumor can be invasive to surrounding tissues and difficult to control. Desmoid tumors can develop virtually at any body site. Superficial desmoids tend to be less aggressive than deep desmoids (abdominal, extra abdominal, mesenteric). These tumors look like dense scar tissue and just like scar tissue, they adhere tenaciously to surrounding structures and organs, and, thus they are commonly difficult to remove. Surgery has been the traditional main mode of therapy for desmoid tumors but up to 20-50% of these tumors recur after surgery.
IntroductionThe Greek word "desmos" which means tendon or band like has been the origin of the term desmoid and was coined by Muller in 1838. Desmoid tumor is called an aggressive fibromatosis as it has similarities with a malignant (cancerous) tumor called fibrosarcoma. However, it is considered benign because it does not metastasize (spread) to other parts of the body.
Desmoid tumors typically affect tissue that is elastic and easily moved, a tumor may exist for a long time before being discovered, growing large and pushing aside surrounding tissue. While each child or adult may experience symptoms differently, the following are the most common symptoms of desmoid tumors. The symptoms of desmoid tumors vary greatly depending on size, location, and spread of the tumor. Some of the common symptoms include the following:
The exact cause of desmoid tumor still remains unknown. Desmoid tumors may present sporadically or as a manifestation of a hereditary syndrome called familial adenomatous polyposis (FAP). FAP is a familial cancer predisposition syndrome which, if left untreated at an early age, almost always results in colorectal cancer. Up to 32% of FAP patients will develop desmoid tumors in their lifetime. These desmoid tumors are the result of mutations, or changes, in a gene called adenomatous polyposis coli (APC).
For most affected individuals, desmoid tumors occur in a sporadic manner, meaning that they are not caused by a predisposing genetic disease. People who develop desmoid tumors in a sporadic manner have no other health problems associated with mutations in the APC gene and have no close family members with the tumors. Repeated irritation or trauma to a certain part of the body, including surgical trauma, has been theorized to increase the risk of desmoid tumor occurrence. Estrogen also seems to play a role in the development of desmoid tumors.
Desmoid tumors are reported to constitute 0.03% of all cancers. When present in individuals with FAP, the prevalence of desmoid tumors is as high as 13%. The estimated incidence in the general population is 2-4 per million people per year. Desmoid tumors are observed to be more common in persons aged 10-40 years than in others but do also occur in young children and older adults. Desmoid tumors most commonly occur in women after childbirth and the gender ratio is 2:1 for females to males. In children, the incidence is the same in both genders.
The most conclusive diagnostic procedure for desmoid tumor is a biopsy (a tissue sample from the tumor taken through a simple surgical procedure). A biopsy is the most important diagnostic test for this tumor. Electron microscopy may be performed in addition to the biopsy for obtaining further clarity and confirmation for the diagnosis. On electron microscopic examination, the spindle cells of desmoid tumors appear to be myofibroblasts. This finding is thought to represent an abnormal proliferation of myofibroblasts, which normally disappear gradually during the later stages of wound healing. Additionally, immunohistochemical stains can be done looking for nuclear accumulation of beta-catenin, a protein that is affected by the genetic mutations often found in desmoid tumors. Nuclear reactivity shows relatively high specificity, detected in up to 90% of desmoids, regardless of site. Finally, antibodies are often examined in desmoid tumors, including smooth muscle actin, desmin and KIT, to aid in distinguishing them from other tumors.
Depending on the extent of the tumor growth and the overall condition of the patient the following treatment options are utilized.
Because desmoid tumor never metastasizes, surgery alone is often the only treatment and hence surgical removal of the tumor is the primary treatment. The recurrence rate for a desmoid tumor is often as high as 50% and hence more than one surgery is commonly needed. The tumor tends to become more aggressive when it recurs after resection. For patients who refuse surgery, are not appropriate candidates for surgery, or have recurrences not responding to repeated surgeries, the following options may be considered:
Radiation therapy may be used as a treatment of recurrent disease or as primary therapy to avoid mutilating surgical resection by using high-energy rays (radiation) from a specialized machine to damage or kill cancer cells and shrink tumors. The radiation may be applied by conventional linear accelerators (radiotherapy treatment machines) or by proton beam therapy. The choice between the two is highly dependent upon the individual patient characteristics.
Anti-inflammatory medication may be given to help manage pain and swelling. In some cases these medications will cause the tumor to slowly shrink. Non-steroidal anti-inflammatory drugs (NSAIDs) and drugs such as Imatinib are being used by physicians to treat desmoid tumors. Imatinib has been shown to effectively treat desmoid tumors that cannot be safely removed via surgical means.
Hormone therapy – Because some hormones seem to increase the growth of desmoid tumors, anti-hormonal medications such as anti-estrogens and prostaglandin inhibitors may also be used in the pharmacologic therapy.
Chemotherapy – If surgeons are unable to remove the tumor because of the size or location as in the case of recurrent extra-abdominal desmoid tumors in which surgery is contraindicated, some types of chemotherapy are used to reduce tumor size. Some of the agents known to inhibit cell growth proliferation are Doxorubicin (Adriamycin, Rubex), Dacarabazine (DTIC-Dome) and Carboplatin (Paraplatin).
Monitoring – After surgery, MRI may be useful for monitoring recurrence. Positron emission tomography Scans (PET) is also growing in popularity for monitoring the recurrence of desmoid tumors as it is a noninvasive imaging technique that creates three-dimensional images of the heart, brain and other organs of the body.
Novel molecular-targeted therapies: Kinases are regulators of cell growth, differentiation, and motility. Because these processes are deregulated in tumors cells, a new class of drugs called receptor kinase inhibitors has been developed. Gleevec and Sorafenib are two kinase inhibitors that are being used in the treatment of desmoid tumors.
Watchful waiting policy: Because desmoid tumors do not metastasize and can be followed closely for growth and because treatment with surgery and/or RT and chemotherapy can cause significant morbidity and even mortality, patients with asymptomatic or minimally symptomatic disease and with stable appearance on screening modalities may appropriately be treated with a period of watchful waiting.
Angiogenesis inhibitors: Newer substances that may be able to prevent the growth of tumors by blocking the formation of new blood vessels that feed the tumors are being currently investigated.
Chemotherapy agents: Researchers are also testing several chemotherapy drugs, or combination of drugs, that could prove to be most effective in treating desmoid tumors to avoid radical management via surgery.
Mutations in the gene for beta-catenin have been found to commonly occur in desmoid tumor. Mutation analysis may soon be used to predict the risk of recurrence and to aid in the design of individual therapies.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Toll free: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
For information about clinical trials conducted in Europe, contact:
Litchman, C, ed. Desmoid Tumors. 1st ed. New York, NY: Springer Publishing; 2012:221.
James WD, Berger TG, ElstonDMeds. Andrews’ Diseases of The Skin: Clinical Dermatology. 11th ed. Philadelphia, PA: W.B. Saunders Company; 2011:959.
Thoene JG, Coker NP, eds.. Physician’s Guide to Rare Diseases. Montvale, NJ: Dowden Publishing Company Inc.; 1995:70-71.
Lev D, Kotilingam D, Wei C, Ballo MT, Zagars GK, Pisters PW, Lazar AA, Patel SR, Benjamin RS, Pollock RE. Optimizing treatment of desmoid tumors. J ClinOnc.2007;25:1785-1791.
Shi B, Zhu Y, Xu Z, et al. Aggressive fibromatosis in the urological system.Report of two adult patients and review of the literature.Urol Int. 2007;78(1):93-6.
Schwartz RA, Trovato MJ, Lambert PC. The desmoid tumor — a locally aggressive neoplasm.Cesko-SlovenskaDermatologie. 2007;82:34-8.
Neri HA, Villagra EJ, Alvarez AC, et al. Ethmoidal desmoid tumor in a pediatric patient.Otolaryngol Head Neck Surg. 2007;136(1):137-8.
Bhama PK, Chugh R, Baker LH, Doherty GM. Gardner’s syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy. World J SurgOncol. 2006;4:96.
Lee JC, Thomas JM, Phillips S, et al. Aggressive fibromatosis: MRI features with pathologic correlation. AJR Am J Roentgenol. 2006;186(1):247-54.
Rajesh A, Sandrasegaran K. Mesenteric desmoid mimicking recurrent testicular cancer. Abdom Imaging. 2005;30(6):777-9.
Mendenhall WM, Zlotecki RA, Morris CG, et al. Aggressive fibromatosis.Am J ClinOncol. 2005;28(2):211-5.
Moon JI, Selvaggi G, Nishida S, et al. Intestinal transplantation for the treatment of neoplastic disease.J SurgOncol. 2005;92(4):284-91.
Erguvan-Dogan B, Dempsey PJ, Ayyar G, Gilcrease MZ.Primary desmoid tumor (extra-abdominal fibromatosis) of the breast. AJR Am J Roentgenol. 2005;185(2):488-9.
Thuret R, Renaudin K, Leclere J, et al. Uncommon malignancies: case 3. Paratesticular desmoplastic small round-cell tumor.J ClinOncol. 2005; 23(25):6253-5.
Brueckl WM, Ballhausen WG, Förtsch T, et al. Genetic testing for germline mutations of the APC gene in patients with apparentlysporadicdesmoid tumors but a family history of colorectal carcinoma. Dis Colon Rectum. 2005;48(6):1275-81.
Buitendijk S, van de Ven CP, Dumans TG, et al. Pediatric aggressive fibromatosis: a retrospective analysis of 13 patients and review of literature. Cancer. 2005;104(5):1090-9.
Sturt NJ, Gallagher MC, Bassett P, et al. Evidence for genetic predisposition to desmoidtumours in familial adenomatous polyposis independent of the germline APC mutation. Gut. 2004; 53(12):1832-6.
Lindor NM, Dozois R, Nelson H, Wolff B, King J, Boardman L, Wilson M, Greene MH, Karnes W, Mesa R, Welch T, Edmonson J, Limburg P. Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. Am J Gastroenterol. 2003; 98(8):1868-74
Dormans JP, Spiegel D, Meyer J, et al. Fibromatoses in childhood: the desmoid/fibromatosis complex. Med PediatrOncol. 2001;37(2):126-31.
Abdelkader M, Riad M, Williams A. Aggressive fibromatosis of the head and neck (desmoidtumours). J Laryngol Otol. 2001;115(10):772-6.
Rai AT, Nguyen TP, Hogg JP, Gabriele FJ.Aggressive fibromatosis of the neck in a patient with Gardner’s syndrome.Neuroradiology. 2001; 43(8):650-2.
Shields CJ, Winter DC, Kirwan WO, Redmond HP. Desmoidtumours.Eur J SurgOncol. 2001; 27(8):701-6.
Schwartz RA, Trovato MJ, Lambert PC. Desmoid Tumor.Medscape.http://emedicine.medscape.com/article/1060887-overviewUpdated: Oct 2, 2014.Accessed May 19, 2015.
Desmoid Tumors.Mayo Clinic.http://www.mayoclinic.org/desmoid-tumors/treatment.htmlMay 27, 2014. Accessed May 19, 2015.
2008, 2012, 2015
The information in NORD’s Rare Disease Database is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.
The content of the website and databases of the National Organization for Rare Disorders (NORD) is copyrighted and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial or public purpose, without prior written authorization and approval from NORD. Individuals may print one hard copy of an individual disease for personal use, provided that content is unmodified and includes NORD’s copyright.
National Organization for Rare Disorders (NORD)
55 Kenosia Ave., Danbury CT 06810 • (203)744-0100